SUBSCRIBE
SUBSCRIBE

Patient recruitment

PRESS RELEASES
Press Releases
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy® in Advanced Breast Cancer
February 26, 2025
 · 
5 min read
Press Releases
NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients
February 24, 2025
 · 
4 min read
Press Releases
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
February 24, 2025
 · 
6 min read
Press Releases
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
February 21, 2025
 · 
4 min read
Press Releases
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
February 14, 2025
 · 
5 min read
Press Releases
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
February 13, 2025
 · 
3 min read
Press Releases
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
February 12, 2025
 · 
6 min read
Press Releases
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
February 12, 2025
 · 
6 min read
Press Releases
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
February 5, 2025
 · 
4 min read
Press Releases
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
February 3, 2025
 · 
7 min read
Press Releases
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
January 30, 2025
 · 
3 min read
Press Releases
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
January 30, 2025
 · 
4 min read
Press Releases
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
January 27, 2025
 · 
6 min read
Press Releases
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
January 22, 2025
 · 
2 min read
Press Releases
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
January 10, 2025
 · 
7 min read
Press Releases
Argon Medical Announces First Patient Enrollment in CLEAN-PE, a Prospective, Multicenter Study of a New Treatment for Pulmonary Embolism
January 9, 2025
 · 
3 min read
Press Releases
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
January 9, 2025
 · 
6 min read
Press Releases
EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
January 9, 2025
 · 
5 min read
Press Releases
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 9, 2025
 · 
7 min read
Press Releases
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 9, 2025
 · 
6 min read
Load More